BJH - volume 4, issue 3, september 2013
D. Bron MD, PhD
The Bruton’s tyrosine kinase protein is expressed in most hematopoietic cells with the exception of T cells and natural killer cells, but the selective effect of Bruton’s tyrosine kinase mutations suggests that its primary functional role is in antigen receptor signalling in B cells. Ibrutinib (=PCI-32765) was designed as a selective and irreversible inhibitor of the Bruton’s tyrosine kinase protein. In vitro, PCI-32765 arrested cell growth and induced apoptosis in human B-cell lymphoma cell lines, and inhibited tumour growth in vivo in xenograft models. A first analysis performed on 116 naive chronic lymphocytic leukaemia patients with a median age of 71 (range: 65 – 84) shows an estimated 22-months progression-free survival rate of 96%; the median progression-free survival or overall survival had not been reached.1 In 61 patients with relapsed/ refractory chronic lymphocytic leukaemia/small lymphocytic lymphoma with a median age of 64 years (range: 40 – 81) and a high-risk cohort (24 patients), the estimated 22-months progression-free survival rate for the 85 relapse/refractory and high-risk patients was 76%. PCI-32765 (ibrutinib) has demonstrated promising activity in studies enrolling older patients with treatment-naive or relapsed/refractory chronic lymphocytic leukaemia and older patients with small lymphocytic lymphoma. Randomised phase III studies in naïve chronic lymphocytic leukaemia/small lymphocytic lymphoma patients are currently on-going.
(BELG J HEMATOL 2013;4(3): 102–105)
Read moreBJH - volume 4, issue 2, june 2013
G. Verhoef MD, PhD, W. Schroyens MD, PhD, D. Bron MD, PhD, C. Bonnet MD, PhD, V. De Wilde MD, PhD, A. Van Hoof MD, PhD, A. Janssens MD, PhD, D. Dierickx MD, PhD, M. André MD, PhD, E. Van den Neste MD, PhD
The guidelines for adult patients in this article are based on 2011 ESMO and NCCN version 4.2011 guidelines and amended for the particular Belgian context of label prescription and reimbursement. Levels of evidence for the use of treatment recommendations are given in square brackets. Statements without grading were considered justifed standard clinical practice by the experts of the BHS-lymphoma working party.
(BELG J HEMATOL 2013;4(2):51–57)
Read moreBJH - volume 4, issue 1, march 2013
M.A. Azerad MD, F. Debaugnies PharmD, A. Demulder MD, PhD, D. Bron MD, PhD, A. Efira MD
Microvesicles (MV) are since quite recently recognized as forming a unique network between cells. These very little fragments (<1 µm size) are actively released from their parent cells and are able to transfer both cellular and nuclear material. Although active debate remains on how to best detect MV, rendering some results questionable, high MV levels have been reported in aggressive tumours and have been correlated with a poor clinical outcome. Some tumour cell derived MV exhibit strong tissue factor dependent procoagulant activity. Their detection could actually predict the thrombotic risk in selected cancer patients. A growing body of evidence suggests cell microvesicles to be a major link between cancer and thrombosis. Current knowledge on MV in cancer will be reviewed here.
(BELG J HEMATOL 2013;1:3–8)
Read moreBJH - 2013, issue BHS Abstractbook, january 2013
P. André , E. Van den Neste MD, PhD, G. Verhoef MD, PhD, D. Bron MD, PhD, A. Van Hoof MD, PhD, P. Zachée MD, PhD, S. van Steenwegen , B. De Prijck MD, N. Straetmans MD, PhD, M. Maerevoet MD, D. Boulet , F. Offner MD, PhD, P. Pierre , V. Mathieux MD, PhD, P. Mineur MD, T. Connerotte MD, M. Federico , J. Raemaekers
BJH - 2013, issue BHS Abstractbook, january 2013
J. Nguyen , B. Bailly MD, P. Sidon , J. Hotton , M. Roos , M. Maerevoet MD, P. Lewalle MD, PhD, N. Meuleman MD, PhD, M. Paesmans , D. Bron MD, PhD
BJH - 2013, issue BHS Abstractbook, january 2013
S. Dubruille PhD, M. Maerevoet MD, R. Roos , V. Vandenbossche , N. Meuleman MD, PhD, Y. Libert PhD, D. Bron MD, PhD
BJH - 2013, issue BHS Abstractbook, january 2013
M. Van Damme , E. Crompot , N. Meuleman MD, PhD, P. Mineur MD, D. Bron MD, PhD, L. Lagneaux , B. Stamatopoulos
Top
To provide the best experiences, we and our partners use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us and our partners to process personal data such as browsing behavior or unique IDs on this site and show (non-) personalized ads. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Click below to consent to the above or make granular choices. Your choices will be applied to this site only. You can change your settings at any time, including withdrawing your consent, by using the toggles on the Cookie Policy, or by clicking on the manage consent button at the bottom of the screen.
